p.31 抽出テキスト

ment Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39: 763-816. PMID: 28886620 42. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med 2020; 382: 1994-2004. PMID: 32222135 43. Acosta S, Björck M. Modern treatment of acute mesenteric ischaemia. Br J Surg 2014; 101: e100-e108. PMID: 24254428 44. Lim S, Halandras PM, Bechara C, et al. Contemporary Management of Acute Mesenteric Ischemia in the Endovascular Era. Vasc Endovascular Surg 2019; 53: 42-50. PMID: 30360689 45. Arthurs ZM, Titus J, Bannazadeh M, et al. A comparison of endovascular revascularization with traditional therapy for the treatment of acute mesenteric ischemia. J Vasc Surg 2011; 53: 698-705. PMID: 21236616 46. Kawasaki R, Miyamoto N, Oki H, et al. Aspiration therapy for acute superior mesenteric artery embolism with an angled guiding sheath and guiding catheter. J Vasc Interv Radiol 2014; 25: 635-639. PMID: 24674219 47. Raupach J, Lojik M, Chovanec V, et al. Endovascular Management of Acute Embolic Occlusion of the Superior Mesenteric Artery: A 12- Year Single-Centre Experience. Cardiovasc Intervent Radiol 2016; 39: 195-203. PMID: 26202388 48. Bisdas T, Stavroulakis K, Beropoulis E, et al. Initial Experience With the 6-F and 8-F Indigo Thrombectomy System for Acute Renovisceral Occlusive Events. J Endovasc Ther 2017; 24: 604-610. PMID: 28548010 49. Kawano M, Azuma M, Hattori Y, et al. Short-term experience with aspiration embolectomy using a ACE68 reperfusion catheter to treat embolic superior mesenteric artery occlusion. Emerg Radiol 2021; 28: 675-678. PMID: 33417115 50. Garzelli L, Ben Abdallah I, Nuzzo A, et al. Endovascular Thrombectomy for Acute Arterial Mesenteric Ischaemia: No Benefit of Mechanical Over Manual Thrombus Aspiration. Eur J Vasc Endovasc Surg 2022; 64: 128-129. PMID: 35568314 51. Xu R, Tang L, Qin S, et al. Percutaneous Mechanical Thrombectomy Using the AcoStream Thrombus Aspiration System for Acute Superior Mesenteric Artery Embolism. Ann Vasc Surg 2024; 106: 264-272. PMID: 38815920 52. Oderich GS, Macedo R, Stone DH, et al. Low Frequency Vascular Disease Research Consortium Investigators. Multicenter study of retrograde open mesenteric artery stenting through laparotomy for treatment of acute and chronic mesenteric ischemia. J Vasc Surg 2018; 68: 470-480. PMID: 29548812 53. Sénémaud JN, Roussel A, Pellenc Q, et al. Retrograde Open Mesenteric Stenting for Acute and Chronic Mesenteric Ischaemia: Results from an Intestinal Stroke Centre. Eur J Vasc Endovasc Surg 2021; 62: 55-63. PMID: 33965329 54. Karampinis I, Keese M, Jakob J, et al. Indocyanine Green Tissue Angiography Can Reduce Extended Bowel Resections in Acute Mesenteric Ischemia. J Gastrointest Surg 2018; 22: 2117-2124. PMID: 29992520 55. Debus ES, Nehler MR, Govsyeyev N, et al. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation 2021; 144: 1104-1116. PMID: 34380322 56. Bonaca MP, Szarek M, Debus ES, et al. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. Clin Cardiol 2022; 45: 1143-1146. PMID: 36251249 57. Govsyeyev N, Nehler M, Conte MS, et al. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. J Vasc Surg 2023; 77: 1107-1118.e2. PMID: 36470531 58. Bedenis R, Lethaby A, Maxwell H, et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2015; 2015: CD000535. PMID: 25695213 59. Belch JJ, Dormandy J, et al. CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52: 825-833. PMID: 20678878 60. Belkin N, Stoecker JB, Jackson BM, et al. Effects of dual antiplatelet

therapy on graft patency after lower extremity bypass. J Vasc Surg 2021; 73: 930-939. PMID: 32777321 61 Sarac TP, Huber TS, Back MR, et al. Warfarin improves the outcome

of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998; 28: 446-457. PMID: 9737454 62. Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-351. PMID: 10665553 63. Johnson WC, Williford WO. Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35: 413-421. PMID: 11877686 64. Aboyans V, Ricco JB, Bartelink MEL, et al. Editor's Choice 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018; 55: 305-368. PMID: 28851596 65. Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-227. PMID: 17634457 66. Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19. PMID: 22077192 67. Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 2017; 389: 1799- 1808. PMID: 28325638 68. Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377: 1319-1330. PMID: 28844192 69. Anand SS, Bosch J, Eikelboom JW, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229. PMID: 29132880 70. Anand SS, Caron F, Eikelboom JW, et al. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol 2018; 71: 2306-2315. PMID: 29540326 71. Hiatt WR, Bonaca MP, Patel MR, et al. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Circulation 2020; 142: 2219-2230. PMID: 33138628 72. Hogan SE, Debus ES, Nehler MR, et al. Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation 2024; 149: 635-637. PMID: 38377256 73. Strobl FF, Brechtel K, Schmehl J, et al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther 2013; 20: 699-706. PMID: 24093324 74. Iida O, Yokoi H, Soga Y, et al. STOP-IC investigators. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013; 127: 2307-2315. PMID: 23652861 75. Miura T, Miyashita Y, Soga Y, et al. DEBATE in SFA Investigators. Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery. Circ Cardiovasc Interv 2018; 11: e006564. PMID: 30354784 76. Soga Y, Iida O, Hirano K, et al. Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia. J Vasc Surg 2011; 54: 1659-1667. PMID: 21872419 77. Iida O, Soga Y, Urasawa K, et al. MDT-2113 SFA Japan Investigators. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial. J Endovasc Ther 2018; 25: 109-117. PMID: 29264999 78. Yokoi H, Ohki T, Kichikawa K, et al. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results. JACC Cardiovasc Interv 2016; 9: 271-277. PMID: 26847118 79. Iida O, Takahara M, Soga Y, et al. One-Year Outcomes of Hepa-

rin-Bonded Stent-Graft Therapy for Real-World Femoropopliteal Lesions and the Association of Patency With the Prothrombotic State Based on the Prospective, Observational, Multicenter Viabahn Stent-